ArQule set to acquire Cyclis Pharma

FRAMINGHAM (09/24/2003) - Last month, ArQule Inc. was set to acquire Cyclis Pharmaceuticals Inc., a privately held cancer therapeutics company. In addition to US$25 million in cash and common stock, ArQule will assume all of the outstanding debt and liabilities of Cyclis, which are estimated to range between $5 million and $6 million. ArQule believes that Cyclis' approach, Activated Checkpoint Therapy (ACT), has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy. Cyclis' lead compound, CO-501, is expected to enter Phase I clinical trials in 2003.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about ArQule

Show Comments